Safety and Effectiveness of the Optilume® BPH Catheter System in a Post-Market Study

NARecruitingINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

February 7, 2024

Primary Completion Date

February 7, 2031

Study Completion Date

February 7, 2031

Conditions
Benign Prostatic Hyperplasia
Interventions
DEVICE

Optilume® BPH Catheter System

The Optilume BPH Catheter System is a combination drug/device minimally invasive surgical therapy (MIST) comprised of an uncoated pre-dilation balloon catheter and a separate drug coated balloon (DCB) catheter. The distal end of each catheter has a semi-compliant, inflatable, double lobe balloon that is used to dilate the prostate. The double-lobe DCB catheter is coated with a proprietary coating containing the active pharmaceutical agent paclitaxel. The drug coating covers the working length of the balloon body.

Trial Locations (5)

33615

RECRUITING

Florida Urology Partners, LLP, Tampa

71106

RECRUITING

Ochsner LSU Health Shreveport - Regional Urology, Shreveport

72211

RECRUITING

Arkansas Urology, Little Rock

78705

RECRUITING

Midtown Urology Associates, Austin

89144

RECRUITING

Sheldon Freedman MD, Ltd, Las Vegas

All Listed Sponsors
lead

Urotronic Inc.

INDUSTRY